NASDAQ:RTTR

Ritter Pharmaceuticals - RTTR Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.

Add

Compare

Today's Range: $0.26
▼
$0.29
50-Day Range: $0.45
▼
$4.09
52-Week Range: $0.15
▼
$1.27

Volume: 125,615 shs
Average Volume: 14.23 million shs
Market Capitalization: $12.32 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Ritter Pharmaceuticals (NASDAQ:RTTR) Stock

Ritter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.

Receive RTTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ritter Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RTTR Stock News Headlines

May 24, 2021 | au.finance.yahoo.com

Docbot Closes Series A Financing Led by Khosla Ventures and Appoints Andrew J. Ritter as CEO

June 10, 2020 | finance.yahoo.com

Qualigen Therapeutics Signs Exclusive License Agreement with the University of Louisville, Plans to Develop AS1411 for the Treatment of COVID-19

June 4, 2020 | finance.yahoo.com

Qualigen Therapeutics Receives U.S. Patent Notice of Allowance for its STARS™ Technology

May 22, 2020 | seekingalpha.com

Ritter to complete Qualigen tie-up today

May 22, 2020 | finance.yahoo.com

Ritter Pharmaceuticals, Inc. Announces Expected Closing of Merger Transaction with Qualigen, Inc.

May 19, 2020 | finance.yahoo.com

Ritter Pharmaceuticals, Inc. Announces Stockholder Approval of Proposals Required for Merger Transaction with Qualigen, Inc.

May 14, 2020 | finance.yahoo.com

Ritter Pharmaceuticals, Inc. Announces Adjournment of its Special Meeting

May 11, 2020 | www.benzinga.com

Ritter Pharmaceuticals Regains Compliance with Nasdaq's Stockholders' Equity Requirement for Continued Listing

May 11, 2020 | finance.yahoo.com

Ritter Pharmaceuticals Regains Compliance with Nasdaq’s Stockholders’ Equity Requirement for Continued Listing

May 7, 2020 | www.nasdaq.com

RTTR Ritter Pharmaceuticals, Inc. Common Stock

May 7, 2020 | www.msn.com

66 Biggest Movers From Yesterday

May 7, 2020 | www.benzinga.com

Thinking about buying stock in Stemline Therapeutics, KLX Energy, Trinity Biotech, Tilray, or Ritter Pharmaceuticals?

May 6, 2020 | finance.yahoo.com

Leading Independent Proxy Advisory Firms Recommend Ritter Pharmaceuticals Shareholders Vote in Favor of its Merger and Each of the Merger Proposals

May 1, 2020 | finance.yahoo.com

Ritter Pharmaceuticals Reports Financial Results for the First Quarter Ended March 31, 2020

April 28, 2020 | finance.yahoo.com

Ritter Pharmaceuticals, Inc. Urges Stockholders to Vote Now on Proposed Merger with Biotech Company, Qualigen Inc.

April 16, 2020 | finance.yahoo.com

Ritter Pharmaceuticals, Inc. Announces Form S-4 Registration Statement Declared Effective by SEC

March 31, 2020 | finance.yahoo.com

Ritter Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2019

March 27, 2020 | www.barrons.com

Ritter Pharmaceuticals Inc.

March 4, 2020 | www.bloomberg.com

Ritter Pharmaceuticals Announces Appointment of John W. Beck as Chief Financial Officer

January 21, 2020 | seekingalpha.com

Ritter Pharma to merger with Qualigen; shares up 28%

January 21, 2020 | finance.yahoo.com

Ritter Pharmaceuticals, Inc. and Qualigen, Inc. Announce Merger Agreement

January 8, 2020 | www.msn.com

50 Healthcare Stocks Moving In Wednesday's Pre-Market Session

December 23, 2019 | www.bloomberg.com

Ritter Pharmaceuticals Announces Last Patient Last Visit in its Phase 3 “Liberatus” Clinical Trial of RP-G28 for Lactose

November 21, 2019 | www.nasdaq.com

Ritter Pharmaceuticals, Inc. Common Stock (RTTR) Institutional Holdings

November 19, 2019 | finance.yahoo.com

What Kind Of Investor Owns Most Of Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR)?

See More Headlines

Receive RTTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ritter Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RTTR Company Calendar

Last Earnings: 5/01/2020
Today: 10/02/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:RTTR
CUSIP: N/A
CIK: 1460702
Web: www.ritterpharmaceuticals.com
Phone: 310-203-1000
Fax: N/A
Employees: 7
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-10,130,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -162.05%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.67
Quick Ratio: 3.67

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.10 per share
Price / Book: 2.67

Miscellaneous

Outstanding Shares: 46,153,000
Free Float: N/A
Market Cap: $12.32 million
Optionable: Not Optionable
Beta: -0.43

Key Executives

Mr. Ira Eliot Ritter (Age 70)
Co-Founder, Exec. Chairman & Chief Strategic Officer

Mr. Andrew J. Ritter (Age 36)
Co-Founder, CEO, Pres, Corp. Sec. & Director

Mr. Michael D. Step (Age 59)
Consultant & Director

Mr. John W. Beck CPA (Age 59)
CPA, Chief Financial Officer

Ms. Ellen F. Mochizuki (Age 52)
Consultant

Key Competitors

View All Competitors

RTTR Stock - Frequently Asked Questions

How were Ritter Pharmaceuticals' earnings last quarter?: Ritter Pharmaceuticals Inc (NASDAQ:RTTR) posted its quarterly earnings data on Friday, May, 1st. The biotechnology company reported ($0.05) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by $0.01.
When did Ritter Pharmaceuticals' stock split?: Shares of Ritter Pharmaceuticals reverse split on Friday, March 23rd 2018. The 1-10 reverse split was announced on Thursday, March 22nd 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 22nd 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What other stocks do shareholders of Ritter Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Ritter Pharmaceuticals investors own include Endologix (ELGX), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), APA (APA), Charles Schwab (SCHW), Genocea Biosciences (GNCA), Hudson Technologies (HDSN), Vicor (VICR), Zoetis (ZTS) and Primo Water (PRMW).

When did Ritter Pharmaceuticals IPO?: (RTTR) raised $20 million in an IPO on Wednesday, June 24th 2015. The company issued 4,000,000 shares at $5.00 per share. Aegis Capital Corp and Chardan Capital Markets acted as the underwriters for the IPO and Barrington Research was co-manager.
What is Ritter Pharmaceuticals' stock symbol?: Ritter Pharmaceuticals trades on the NASDAQ under the ticker symbol "RTTR."
What is Ritter Pharmaceuticals' stock price today?: One share of RTTR stock can currently be purchased for approximately $0.27.
How much money does Ritter Pharmaceuticals make?: Ritter Pharmaceuticals (NASDAQ:RTTR) has a market capitalization of $12.32 million.
How can I contact Ritter Pharmaceuticals?: Ritter Pharmaceuticals' mailing address is 1880 CENTURY PARK EAST SUITE 1000, LOS ANGELES CA, 90067. The official website for the company is www.ritterpharmaceuticals.com. The biotechnology company can be reached via phone at 310-203-1000 or via email at john@ritterpharma.com.

This page (NASDAQ:RTTR) was last updated on 10/2/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms